Clinical trial · Observational
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
Post-Marketing Observational Study (PMOS) to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study to assess the real-life management and use of healthcare resources during the initiation of: * Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. * Venetoclax in participants with CLL with the deletion of the short arm of chromosome 17 (del\[17p\]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Participants receiving venetoclax
- description
- Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
Primary outcomes (13)
- measure
- Duration of Prophylactic Hospitalization
- timeFrame
- Up to approximately 6 weeks
- description
- Duration of prophylactic hospitalization is defined as the date of discharge - the date of admission + 1.
- measure
- Number of Hours from Dosing to Blood Draw
- timeFrame
- Baseline (Day 0)
- description
- Number of hours between laboratory assessments and the first dose of each ramp-up dose for venetoclax
- measure
- Intravenous (IV) fluid hydration
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study. * Has chronic lymphocytic leukemia (CLL) and has received at least one prior therapy. Exclusion Criteria: * Currently participating in an interventional study. * Has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of CLL.
References
Publications (0)
Data not yet available